Berberine Suppressed Tumor Growth through Regulating Fatty Acid Metabolism and Triggering Cell Apoptosis via Targeting FABPs

Lingli Li, Ze Peng, Qian Hu, Lijun Xu, Xin Zou, Yan Yu, Dongmei Huang, Ping YiEvidence-based 2020 · DOI

TL;DR

This study reveals that berberine, a natural compound, effectively suppresses gastric cancer growth by disrupting fatty acid metabolism and inducing apoptosis. By targeting fatty acid-binding proteins (FABPs), berberine leads to an accumulation of fatty acids within cancer cells, ultimately triggering programmed cell death.

What Problem Does This Paper Address?

Gastric cancer remains a significant global health challenge, particularly in China, with high mortality rates often linked to late diagnosis and less effective treatment strategies. While traditional Chinese medicine has long utilized compounds like berberine for various ailments, its precise mechanisms against gastric cancer, especially concerning metabolic pathways, are not fully understood. This paper aims to elucidate how berberine exerts its anti-cancer effects by investigating its impact on lipid metabolism, a process known to be reprogrammed in cancer cells and crucial for their survival and proliferation. Specifically, the researchers sought to understand if berberine's therapeutic actions are mediated through its influence on fatty acid metabolism and subsequent induction of apoptosis.

Methods

The researchers employed a multi-pronged approach combining in vitro and in vivo experiments.

  • In vitro studies:
    • MTT assays: Used to assess the cytotoxic and antiproliferative effects of berberine on MGC803 human gastric cancer cells.
  • Flow cytometry (Annexin V-FITC/PI staining): Employed to quantify the rate of apoptosis induced by berberine.
  • Western blotting: Utilized to measure the protein expression levels of key molecules involved in apoptosis (Bcl-2, Bax, cleaved-caspase3) and lipid metabolism (FABP4, FABP5, PPARα).
  • Biochemical assays: Used to determine the levels of triglycerides and total cholesterol in both the cancer cells and their surrounding media.
  • FABP inhibitor treatment: The specific FABP inhibitor BMS309403 was used to mimic and validate the effects of berberine on lipid metabolism and apoptosis.
  • In vivo studies:
    • Xenograft models: MGC803 gastric cancer cells were implanted into immunodeficient mice (Balb/c nude mice) to create subcutaneous tumors.
  • Treatment: Mice were treated with berberine via intragastric administration.
  • Tumor assessment: Tumor volume, weight, and body weight were monitored.
  • Histological analysis: Hematoxylin and eosin (H&E) staining was performed on tumor tissues to assess cellular morphology.
  • TUNEL assays: Used to detect apoptosis in tumor tissues.
  • Western blotting: Performed on tumor tissue lysates to analyze the expression of apoptosis and lipid metabolism-related proteins.

Datasets

Not discussed in the paper. The study utilized established human gastric cancer cell lines (MGC803) and commercially available reagents.

Key Insights and Ideas

  • Berberine's dual action: The study highlights that berberine doesn't just kill cancer cells; it does so by specifically targeting a critical metabolic pathway (fatty acid metabolism) and then leveraging that disruption to trigger apoptosis.
  • FABPs as key targets: The research strongly implicates Fatty Acid-Binding Proteins (FABPs) as central mediators of berberine's effects. Inhibiting FABPs with a specific drug mimicked berberine's actions, suggesting FABPs are a crucial link in the chain.
  • Metabolic reprogramming in cancer: The findings underscore how cancer cells rely on altered lipid metabolism for their growth and survival, and how targeting these metabolic vulnerabilities can be a potent anti-cancer strategy.
  • Accumulation of fatty acids as a trigger: The unexpected finding that berberine increases fatty acid levels within cancer cells, rather than depleting them, is a key insight. This accumulation appears to be the signal that initiates the apoptotic cascade.

Key Results

  • Antiproliferative effects: Berberine significantly inhibited the proliferation of MGC803 gastric cancer cells in a time- and dose-dependent manner in vitro.
  • Apoptosis induction: Berberine treatment led to a dose-dependent increase in apoptosis in MGC803 cells, evidenced by increased Annexin V-FITC/PI staining and altered expression of apoptosis-related proteins (decreased Bcl-2, increased Bax, and activated caspase-3).
  • Lipid metabolism modulation: Berberine treatment increased triglyceride levels in MGC803 cells and their supernatants. Crucially, it suppressed the protein expression of FABP4, FABP5, and PPARα, key regulators of fatty acid uptake and metabolism.
  • FABP inhibitor validation: The FABP inhibitor BMS309403 recapitulated berberine's effects, reducing cell viability, inducing apoptosis, and increasing triglyceride levels, further supporting FABPs as targets.
  • In vivo efficacy: In xenograft models, berberine significantly reduced tumor volume and weight, and induced apoptosis in tumor tissues. It also suppressed FABP and PPARα expression in vivo.
  • No significant side effects: Berberine treatment did not significantly affect the body weight of the mice, suggesting a favorable safety profile in this context.

Limitations and Future Work

  • Specificity of FABP inhibition: While BMS309403 is a FABP inhibitor, the paper notes it targets FABP3-5 and -7. Further research could explore the specific roles of individual FABP isoforms in berberine's mechanism.
  • Mechanistic details of fatty acid accumulation: While the accumulation of fatty acids is linked to apoptosis, the precise downstream signaling pathways triggered by this accumulation require further investigation.
  • Broader applicability: The study focused on MGC803 gastric cancer cells. Future work could explore berberine's effects on other gastric cancer subtypes or different cancer types that exhibit similar metabolic vulnerabilities.
  • Clinical translation: The promising in vitro and in vivo results warrant further investigation into the clinical efficacy and safety of berberine as an adjuvant therapy for gastric cancer.

Summary updated

Abstract

Berberine exerted anticancer effects on human gastric cancer both in vitro and in vivo by inducing apoptosis, which was due to the reduced protein expression of FABPs and the accumulation of fatty acid.
BibTeX
@inproceedings{li2020berberine,
  author = {Lingli Li and Ze Peng and Qian Hu and Lijun Xu and Xin Zou and Yan Yu and Dongmei Huang and Ping Yi},
  title = {{Berberine Suppressed Tumor Growth through Regulating Fatty Acid Metabolism and Triggering Cell Apoptosis via Targeting FABPs}},
  booktitle = {Evidence-based},
  year = {2020},
  doi = {10.1155/2020/6195050},
}
Figure